Pancreatic Neuroendocrine Tumor：Factor of Surgery Influencing Survival

Status Not yet recruiting

Clinical Trial Summary

Investigator determined the factor of surgery associated with the survival of pancreatic neuroendocrine tumor.

Clinical Trial Description

The variables including clinical characteristics, surgical data and pathological findings are examined by univariate and multivariate analyses. ;

Study Design

Observational Model: Case-Only, Time Perspective: Retrospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02624154
Study type	Observational
Source	First Affiliated Hospital, Sun Yat-Sen University
Contact	Qinchang Chen, Doctor
Phone	18819430530
Email	337809622@qq.com
Status	Not yet recruiting
Phase	N/A
Start date	December 2015
Completion date	December 2016

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05566093` - EUS-FNI for Nonfunctional Pancreatic Neuroendocrine Tumors	N/A
Completed	`NCT00970970` - Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease
Recruiting	`NCT05568017` - Neoadjuvant PRRT With Y-90-DOTATOC in pNET	Phase 2
Not yet recruiting	`NCT06024343` - Minimally Invasive Pancreatic Enucleation With Main Pancreatic Duct Repair or Reconstruction	N/A
Recruiting	`NCT03891784` - Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors	Phase 2
Recruiting	`NCT03204019` - A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor	Phase 2
Completed	`NCT00804336` - Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors	Phase 1
Recruiting	`NCT05997056` - Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors	Phase 2
Not yet recruiting	`NCT06158516` - A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors	Phase 2
Recruiting	`NCT04119024` - Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors	Phase 1
Recruiting	`NCT05040360` - Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors	Phase 2
Completed	`NCT00576680` - RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors	Phase 1/Phase 2
Recruiting	`NCT05610826` - Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver	Phase 1/Phase 2
Active, not recruiting	`NCT03074513` - Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors	Phase 2
Completed	`NCT03967951` - CT Radiomic Features of Pancreatic Neuroendocrine Neoplasms
Completed	`NCT01024387` - AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors	Phase 2
Not yet recruiting	`NCT03435770` - Evaluation of Safety and Feasibility of EUS-guided RFA for Solid Pancreatic Neoplasms	N/A
Recruiting	`NCT04134832` - Study of Pancreatic Neuroendocrine Tumors and Carcinomas in Alsace Region
Recruiting	`NCT05554744` - EUS-FNI for MEN1-related Pancreatic Neuroendocrine Tumors	N/A
Completed	`NCT02159989` - Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	Phase 1